Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cantargia AB
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Net Issuance of Common Stock
kr59.3m
CAGR 3-Years
-53%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Net Issuance of Common Stock
-kr417k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Net Issuance of Common Stock
kr990k
CAGR 3-Years
-47%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Net Issuance of Common Stock
kr476m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
53%
BioArctic AB
STO:BIOA B
Net Issuance of Common Stock
kr15m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Cantargia AB's Net Issuance of Common Stock?
Net Issuance of Common Stock
59.3m SEK

Based on the financial report for Sep 30, 2024, Cantargia AB's Net Issuance of Common Stock amounts to 59.3m SEK.

What is Cantargia AB's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-11%

The average annual Net Issuance of Common Stock growth rates for Cantargia AB have been -53% over the past three years , -11% over the past five years .

Back to Top